S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
NASDAQ:LNTH

Lantheus (LNTH) Stock Forecast, Price & News

$69.64
+0.11 (+0.16%)
(As of 03:28 PM ET)
Compare
Today's Range
$68.44
$70.44
50-Day Range
$60.27
$87.95
52-Week Range
$47.46
$100.85
Volume
722,924 shs
Average Volume
1.02 million shs
Market Capitalization
$4.77 billion
P/E Ratio
169.85
Dividend Yield
N/A
Price Target
$119.33

Lantheus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.9% Upside
$119.33 Price Target
Short Interest
Bearish
7.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.71mentions of Lantheus in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.54 M Sold Last Quarter
Proj. Earnings Growth
7.71%
From $5.19 to $5.59 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

136th out of 972 stocks

Diagnostic Substances Industry

3rd out of 13 stocks


LNTH stock logo

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Price History

LNTH Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Lantheus: Not Quite Ready To Take The Plunge
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Lantheus Holdings Inc
Lantheus to discontinue radiotherapy Azedra
Mizuho Securities Remains a Buy on Lantheus (LNTH)
Lantheus (LNTH) Receives a Buy from Truist Financial
B.Riley Financial Keeps Their Buy Rating on Lantheus (LNTH)
JMP Securities Reaffirms Their Buy Rating on Lantheus (LNTH)
Lantheus Holdings: Q2 Earnings Snapshot
Truist Financial Remains a Buy on Lantheus (LNTH)
Lantheus (LNTH) Gets a Buy from Truist Financial
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings
8/03/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$119.33
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$104.00
Forecasted Upside/Downside
+71.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$28.07 million
Pretax Margin
1.72%

Debt

Sales & Book Value

Annual Sales
$935.06 million
Cash Flow
$5.04 per share
Book Value
$6.50 per share

Miscellaneous

Free Float
67,405,000
Market Cap
$4.76 billion
Optionable
Optionable
Beta
0.68
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Mary Anne HeinoMs. Mary Anne Heino (Age 63)
    CEO & Director
    Comp: $2.23M
  • Mr. Paul M. BlanchfieldMr. Paul M. Blanchfield (Age 42)
    Pres
    Comp: $962.41k
  • Mr. Robert J. Marshall Jr.Mr. Robert J. Marshall Jr. (Age 56)
    CFA, CFO & Treasurer
    Comp: $1.06M
  • Mr. Daniel M. NiedzwieckiMr. Daniel M. Niedzwiecki (Age 46)
    Chief Admin. Officer, Gen. Counsel & Corp. Sec.
    Comp: $871.93k
  • Mr. Etienne  MontagutMr. Etienne Montagut (Age 48)
    Chief Bus. Officer
    Comp: $789.15k
  • Ms. Andrea  SabensMs. Andrea Sabens (Age 44)
    Chief Accounting Officer
  • Ms. Dorothy Barr
    Sr. VP of Manufacturing & Technical Operations
  • Mr. Mark Richard Kinarney
    Sr. Director of Investor Relations
  • Ms. Linda S. Lennox (Age 57)
    VP of Corp. Communications & Chief of Staff
  • Ms. Carol  WalkerMs. Carol Walker (Age 60)
    Sr. VP of Quality













LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price forecast for 2023?

5 equities research analysts have issued 1 year price targets for Lantheus' stock. Their LNTH share price forecasts range from $104.00 to $130.00. On average, they anticipate the company's stock price to reach $119.33 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 36.4% and is now trading at $69.53.
View the best growth stocks for 2023 here
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, August, 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.17. The medical equipment provider had revenue of $321.70 million for the quarter, compared to analyst estimates of $306.48 million. Lantheus had a trailing twelve-month return on equity of 67.18% and a net margin of 2.97%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its third quarter 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $1.30-$1.35 for the period, compared to the consensus earnings per share estimate of $1.37. The company issued revenue guidance of $310.00 million-$315.00 million, compared to the consensus revenue estimate of $316.89 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $69.53.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.76 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Lantheus have?

The company employs 698 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -